Off-target effects by siRNA can induce toxic phenotype
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Although recent microarray studies have provided evidence of RNA interference (RNAi)-mediated off-target gene modulation, little is known about whether these changes induce observable phenotypic outcomes. Here we show that a fraction of randomly selected small inhibitory RNAs (siRNAs) can induce changes in cell viability in a target-independent fashion. The observed toxicity requires an intact RNAi pathway and can be eliminated by the addition of chemical modifications that reduce off-target effects. Furthermore, an analysis of toxic and nontoxic duplexes identifies a strong correlation between the toxicity and the presence of a 4-base-pair motif (UGGC) in the RISC-entering strand of toxic siRNA. This article provides further evidence of siRNA-induced off-target effects generating a measurable phenotype and also provides an example of how such undesirable phenotypes can be mitigated by addition of chemical modifications to the siRNA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370 · cited 1×
“Recent investigations have demonstrated that transcripts having <100% complementarity with an siRNA can be targeted for knockdown by the RNAi pathway (Jackson et al. 2003; Haley and Zamore 2004; Birmingham et al. 2006).”
BackgroundRational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094
Self-citationHuman Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs
Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng, G., & Tuschl, T. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.07.007 · Cited by 2,052
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate
Elbashir, S. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6877 · Cited by 1,449
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., et al. (2006) · Nature Methods · doi:10.1038/nmeth854 · Cited by 920
Self-citationInvolvement of MicroRNA in AU-Rich Element-Mediated mRNA Instability
Jing, Q., Huang, S., Guth, S., Zarubin, T., Motoyama, A., Chen, J., Di Padova, F., Lin, S.-C., Gram, H., & Han, J. (2005) · Cell · doi:10.1016/j.cell.2004.12.038 · Cited by 849
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789
Self-citation
Cited by
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
p53 Activation by Knockdown Technologies
Robu, M. E., Larson, J. D., Nasevicius, A., Beiraghi, S., Brenner, C., Farber, S. A., & Ekker, S. C. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030078 · Cited by 999
RNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789
Self-citationThe Chemical Biology of Aptamers
Mayer, G. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200804643 · Cited by 592
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Nonviral delivery of synthetic siRNAs in vivo
Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Chemically modified siRNA: tools and applications
Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431
Identification of genes that regulate epithelial cell migration using an siRNA screening approach
Simpson, K. J., Selfors, L. M., Bui, J., Reynolds, A., Leake, D., Khvorova, A., & Brugge, J. S. (2008) · Nature Cell Biology · doi:10.1038/ncb1762 · Cited by 406
Self-citationTherapeutic siRNA: State-of-the-Art and Future Perspectives
Friedrich, M., & Aigner, A. (2022) · BioDrugs · doi:10.1007/s40259-022-00549-3 · Cited by 396
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013243 · Cited by 388
RETRACTED: Secondary siRNAs Result from Unprimed RNA Synthesis and Form a Distinct Class
Sijen, T., Steiner, F. A., Thijssen, K. L., & Plasterk, R. H. A. (2007) · Science · doi:10.1126/science.1136699 · Cited by 383
RetractedDistance constraints between microRNA target sites dictate efficacy and cooperativity
Sætrom, P., Heale, B. S. E., Snøve, O., Aagaard, L., Alluin, J., & Rossi, J. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm133 · Cited by 375
RNA Interference: From Basic Research to Therapeutic Applications
Kurreck, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802092 · Cited by 335
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
On the art of identifying effective and specific siRNAs
Pei, Y., & Tuschl, T. (2006) · Nature Methods · doi:10.1038/nmeth911 · Cited by 302
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S.-Y., Robell, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 295
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 279
PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
Gu, S., Cui, D., Chen, X., Xiong, X., & Zhao, Y. (2018) · BioEssays · doi:10.1002/bies.201700247 · Cited by 231
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
“A number of immunestimulatory GU- or U-rich motifs can trigger TLR7 activation such as GUCCUUCAA (Judge et al., 2005), UGUGU (Sioud, 2006), UGGC (Fedorov et al., 2006), UCA (Jurk et al., 2011), and GU (Diebold et al., 2004; Heil et al., 2004) whereas AU-rich motif primarily stimulate TLR8 (Forsbach et al., 2008).”
BackgroundNanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Metadata
- Authors
- Fedorov, Y., Anderson, E. M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W. S., & Khvorova, A.
- Venue
- RNA
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2006-05-08
- Volume
- 12
- Issue
- 7
- Pages
- 1188-1196
- ISSN
- 1355-8382 (ISSN-L)
- 1469-9001
- OpenAlex
- W2144510218
- Cited by
- 490
- References
- 18
- FWCI
- 15.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.